1.64 USD
+0.03 (+1.86%)
1.62 USD
-0.02 (-1.22%)
We assign a fundamental rating of 3 out of 10 to OGI. OGI was compared to 192 industry peers in the Pharmaceuticals industry. OGI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, OGI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
OGI had negative earnings in the past year.
OGI had a positive operating cash flow in the past year.
OGI had negative earnings in each of the past 5 years.
In the past 5 years OGI reported 4 times negative operating cash flow.
1.2 Ratios
OGI has a Return On Assets of 1.38%. This is amongst the best in the industry. OGI outperforms 81.77% of its industry peers.
The Return On Equity of OGI (2.02%) is better than 82.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.38% | ||
| ROE | 2.02% | ||
| ROIC | N/A |
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 3.47%, OGI belongs to the best of the industry, outperforming 80.73% of the companies in the same industry.
OGI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.47% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OGI has been increased compared to 1 year ago.
Compared to 5 years ago, OGI has more shares outstanding
The debt/assets ratio for OGI is higher compared to a year ago.
2.2 Solvency
OGI has an Altman-Z score of -0.38. This is a bad value and indicates that OGI is not financially healthy and even has some risk of bankruptcy.
OGI has a Altman-Z score (-0.38) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.14 indicates that OGI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.14, OGI perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.38 |
ROIC/WACCN/A
WACC7.98%
2.3 Liquidity
OGI has a Current Ratio of 2.59. This indicates that OGI is financially healthy and has no problem in meeting its short term obligations.
OGI has a Current ratio (2.59) which is in line with its industry peers.
OGI has a Quick Ratio of 1.42. This is a normal value and indicates that OGI is financially healthy and should not expect problems in meeting its short term obligations.
OGI has a worse Quick ratio (1.42) than 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.59 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
OGI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.88%, which is quite impressive.
The Revenue has grown by 38.86% in the past year. This is a very strong growth!
Measured over the past years, OGI shows a quite strong growth in Revenue. The Revenue has been growing by 14.73% on average per year.
EPS 1Y (TTM)98.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-253.85%
Revenue 1Y (TTM)38.86%
Revenue growth 3Y26.37%
Revenue growth 5Y14.73%
Sales Q2Q%72.41%
3.2 Future
Based on estimates for the next years, OGI will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.96% on average per year.
Based on estimates for the next years, OGI will show a quite strong growth in Revenue. The Revenue will grow by 18.32% on average per year.
EPS Next Y119.5%
EPS Next 2Y41.55%
EPS Next 3Y28.91%
EPS Next 5Y19.96%
Revenue Next Year57.11%
Revenue Next 2Y34.49%
Revenue Next 3Y26.71%
Revenue Next 5Y18.32%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
OGI is valuated quite expensively with a Price/Forward Earnings ratio of 1520.43.
67.71% of the companies in the same industry are more expensive than OGI, based on the Price/Forward Earnings ratio.
OGI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1520.43 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates OGI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as OGI's earnings are expected to grow with 28.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.55%
EPS Next 3Y28.91%
5. Dividend
5.1 Amount
No dividends for OGI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.64
+0.03 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.05%
Inst Owner Change19.77%
Ins Owners2.53%
Ins Owner ChangeN/A
Market Cap220.30M
Revenue(TTM)223.82M
Net Income(TTM)7.77M
Analysts77.5
Price Target2.19 (33.54%)
Short Float %5.46%
Short Ratio7.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)376.4%
Min EPS beat(2)-164.03%
Max EPS beat(2)916.83%
EPS beat(4)1
Avg EPS beat(4)56.27%
Min EPS beat(4)-400%
Max EPS beat(4)916.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.51%
Min Revenue beat(2)3.01%
Max Revenue beat(2)6%
Revenue beat(4)3
Avg Revenue beat(4)-0.06%
Min Revenue beat(4)-12.23%
Max Revenue beat(4)6%
Revenue beat(8)5
Avg Revenue beat(8)1.52%
Revenue beat(12)6
Avg Revenue beat(12)-1.43%
Revenue beat(16)9
Avg Revenue beat(16)0.17%
PT rev (1m)-0.07%
PT rev (3m)-1.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1520.43 | ||
| P/S | 1.38 | ||
| P/FCF | N/A | ||
| P/OCF | 112.35 | ||
| P/B | 0.8 | ||
| P/tB | 1.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0
Fwd EY0.07%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)0.01
OCFY0.89%
SpS1.19
BVpS2.04
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.38% | ||
| ROE | 2.02% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3.47% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.3%
ROA(5y)-30.36%
ROE(3y)-36.4%
ROE(5y)-36.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 122.48% | ||
| Cap/Sales | 8.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.59 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | -0.38 |
F-Score3
WACC7.98%
ROIC/WACCN/A
Cap/Depr(3y)118.74%
Cap/Depr(5y)166.77%
Cap/Sales(3y)18.54%
Cap/Sales(5y)32.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-253.85%
EPS Next Y119.5%
EPS Next 2Y41.55%
EPS Next 3Y28.91%
EPS Next 5Y19.96%
Revenue 1Y (TTM)38.86%
Revenue growth 3Y26.37%
Revenue growth 5Y14.73%
Sales Q2Q%72.41%
Revenue Next Year57.11%
Revenue Next 2Y34.49%
Revenue Next 3Y26.71%
Revenue Next 5Y18.32%
EBIT growth 1Y-79.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year148.17%
EBIT Next 3Y46.25%
EBIT Next 5Y30.71%
FCF growth 1Y78.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.64%
OCF growth 3YN/A
OCF growth 5YN/A
ORGANIGRAM GLOBAL INC / OGI FAQ
Can you provide the ChartMill fundamental rating for ORGANIGRAM GLOBAL INC?
ChartMill assigns a fundamental rating of 3 / 10 to OGI.
What is the valuation status of ORGANIGRAM GLOBAL INC (OGI) stock?
ChartMill assigns a valuation rating of 1 / 10 to ORGANIGRAM GLOBAL INC (OGI). This can be considered as Overvalued.
What is the profitability of OGI stock?
ORGANIGRAM GLOBAL INC (OGI) has a profitability rating of 3 / 10.
What is the earnings growth outlook for ORGANIGRAM GLOBAL INC?
The Earnings per Share (EPS) of ORGANIGRAM GLOBAL INC (OGI) is expected to grow by 119.5% in the next year.